Sen-Jam Pharmaceutical (2022)

About this raise

Sen-Jam Pharmaceutical, with a valuation of $25 million, is raising funds on Wefunder. The pharmaceutical company makes highly accessible, safe, and affordable drugs that work. The drugs of Sen-Jam Pharmaceutical combine NSAIDs and antihistamines to prevent inflammation and associated pain. Sen-Jam Pharmaceutical is majorly targeting opioid withdrawal, alcohol hangover prevention, and COVID-19 therapeutic. Jim Iversen and Jackie Iversen founded Sen-Jam Pharmaceutical in August 2017. The current crowdfunding campaign has a minimum target of $50,000 and a maximum target of $1,070,000. The campaign proceeds will be used for product development, regulatory affairs, marketing, communications, and intellectual property advancement.

Expand

Investment Overview

Invested this round: $1,008,951

Deal Terms

Total Commitments

Platform
Wefunder
Start Date
12/02/2021
Close Date
07/31/2022
Min. Goal
$50,000
Max Goal
$1,070,000
Min. Investment

$100

Security Type

Convertible Note

Company Stage

Early Stage

SEC Filing Type

RegCF    Open SEC Filing

Early Bird Val. Cap

$20,000,000

Valuation Cap

$25,000,000

Discount

20%

Company & Team

Company

Year Founded
2017
Industry
Healthcare & Pharmaceuticals
Tech Sector
Biotech
Distribution Model
B2B
Margin
High
Capital Intensity
High
Location
Huntington, New York
Business Type
Growth
Company Website
Visit Website

Team

Employees
4
Prior Founder Exits?
Yes
Founder Name
Jim Iversen
Title
CEO
Founder Name
Jacqueline Iversen
Title
Head of Clinical Development

Financials

 Revenue
$0
 Monthly Burn
$30,743
 Runway
0.4 months

Summary Profit and Loss Statement

Most Recent Year Prior Year

Revenue

$0

$0

COGS

$0

$0

Tax

$0

$860

 

 

Net Income

$-368,918

$-280,006

Summary Balance Sheet

Most Recent Year Prior Year

Cash

$12,240

$174

Accounts Receivable

$0

$0

Total Assets

$634,559

$670,364

Short-Term Debt

$22,039

$0

Long-Term Debt

$395,075

$0

Total Liabilities

$417,114

$0

Create a free account today to gain access to Kingscrowd analytics and financials.

Upgrade to gain access

Pay Monthly
Annually (2 months free)

Edge

$12.50 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific Kingscrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings Kingscrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars

Company Funding & Growth

Funding history

Close Date Platform Valuation Total Raised Security Type Status Reg Type
04/08/2025 Wefunder $80,000,000 $3,373,293 Convertible Note Funded RegCF / RegD 506(c)
01/06/2024 Self Managed - - Convertible Note Funded RegD 506(c)
01/11/2023 StartEngine $69,979,019 $312,093 Equity - Common Funded RegCF
07/31/2022 Wefunder $25,000,000 $1,008,951 Convertible Note Funded RegCF
Create a free account today to gain access to Kingscrowd analytics.

Growth Charts

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Valuation History

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Employee History

Founder Interview

Sen-Jam Pharmaceutical Founder Jim Iversen on Making Effective and Affordable Drugs

Prescription drug prices in the United States are painfully high. Americans pay more than twice as much as other countries for medication. This can weigh especially heavily on individuals without insurance who are struggling to make ends meet. 

In recognition of this problem, Sen-Jam Pharmaceutical aims to develop and sell affordable and effective oral anti-inflammation medicine. The company is working on eight products to address specific conditions, including COVID-19, opioid withdrawal, and hangovers. We reached out to co-founder and CEO Jim Iversen to learn more about the origins of the business and its plans following the raise.

Note: This interview was conducted over phone and email. It has been lightly edited for clarity and length.

Read Founder Interview

Add to portfolio
Sen-Jam Pharmaceutical on Wefunder 2021
Platform: Wefunder
Security Type: Convertible Note
Valuation: $25,000,000

Follow company

Follow Sen-Jam Pharmaceutical on Wefunder 2021

Buy Sen-Jam Pharmaceutical's Deal Report

Warning: according to the close date for this deal, Sen-Jam Pharmaceutical may no longer be accepting investments.

Sen-Jam Pharmaceutical Deal Report

Get Kingscrowd's comprehensive report on Sen-Jam Pharmaceutical including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Sen-Jam Pharmaceutical is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Sen-Jam Pharmaceutical deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge